Narasimhan
Biotech

Novartis CEO keeps faith in Avidity despite $1.9B hit from fail

Vas Narasimhan insisted that the phase 3 fail for del-desiran is just a “bump” in the pharma’s wider plans for the drug, despite costing $1.9 billion.
James Waldron Oct 27, 2026 3:48am
Incyte

ESMO: Incyte claims ‘neck and neck’ KRAS G12D race with RevMed

Oct 26, 2026 9:45am
Weight loss pills Obesity treatment

Why Corxel picked SPAC route to take obesity biotech public

Oct 27, 2026 6:00am
digital dollar with tech background

Anthropic details drug R&D ambitions, risks in IPO filing

Oct 26, 2026 2:00pm
Businesspeople walking towards a bright light at the end of a white corridor

Artiva lays off staff after deaths, durability sink cell therapy

Oct 27, 2026 8:40am
ESMO 2026

From RAS rivalry to leaked readouts, ESMO brought the data drama

Oct 27, 2026 8:00am
More News

Aspen, Bambusa both shoot for $134M IPOs

Oct 27, 2026 7:36am

BMS joins 3-year collab to boost cancer trial participation

Oct 27, 2026 5:00am

GSK’s B7-H3 ADC drives 67% cancer risk reduction in phase 3

Oct 27, 2026 3:28am

Boehringer, Microsoft explore digital twins for clinical trials

Oct 26, 2026 2:49pm